Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page's revision label was updated to v3.5.5, indicating a new release of the page content without altering the study details.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, indicating a small update to the page metadata. This reflects an editorial change to the ClinicalTrials.gov record rather than any substantive study information.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page now displays a new revision label: Revision: v3.5.3, replacing v3.5.2. This signals an update to the page version, with no evident public content changes.SummaryDifference0.0%

- Check57 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check85 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page. The change does not modify study data or user-facing functionality.SummaryDifference0.0%

- Check92 days agoChange DetectedSite version updated from v3.4.2 to v3.4.3. No observable changes to the study content or user-visible features.SummaryDifference0.0%

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.